98%
921
2 minutes
20
The gastrointestinal symptoms of irritable bowel syndrome are strongly related to impaired quality of life (QOL), especially in diarrhea-predominant. The gene polymorphisms associated with serotonin, or 5-hydroxytryptamine, alter gastrointestinal symptoms and mental status. We aimed to evaluate the effects of gene polymorphisms on gastrointestinal symptoms, psychological conditions, and QOL, and compare these between patients with diarrhea-predominant irritable bowel syndrome ( = 62) and healthy controls ( = 64). The gene polymorphisms of 5-HTTLPR, 5-HTTVNTR, TPH1 rs453773, and TPH1 rs211105 were evaluated. Gastrointestinal symptoms, depressive state, and QOL were assessed using the Gastrointestinal Symptom Rating Scale, Self-rating Depression Scale, and Short-Form-36. Gene polymorphisms did not significantly differ in frequency between the two groups. The scores for diarrhea, abdominal pain, and indigestion significantly correlated with the physical component summary score. Only the group of patients with diarrhea-predominant irritable bowel syndrome showed a significant correlation between the TPH1 rs211105 T/T genotype and lower scores for role physical and mental health, and higher scores for indigestion and diarrhea. 5-HTTLPR l/s was associated with lower score of role emotional in the diarrhea-predominant irritable bowel syndrome and higher scores in the controls. The gene polymorphisms of 5-hydroxytryptamine signaling effected gastrointestinal symptoms and QOL, especially of the patients with diarrhea-predominant irritable bowel syndrome.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990411 | PMC |
http://dx.doi.org/10.3164/jcbn.17-76 | DOI Listing |
Intern Med
September 2025
Respiratory Medicine and Infectious Diseases, Oita University Faculty of Medicine, Japan.
Objective Although nintedanib is commonly used to treat interstitial lung disease (ILD), its clinical utility is often limited by adverse gastrointestinal events. Ramosetron, a selective 5-HT receptor antagonist, has shown efficacy in managing irritable bowel syndrome; however, its effects on nintedanib-associated abdominal symptoms remain unclear. This study evaluated the effect of ramosetron on continuation of nintedanib therapy.
View Article and Find Full Text PDFGut
September 2025
Gastrointestinal Genetics Lab, CIC bioGUNE - BRTA, Derio, Spain
Eur J Gastroenterol Hepatol
August 2025
Department of Surgery, Aristotle University of Thessaloniki, Thessaloniki.
Background: The use of probiotics as a treatment for irritable bowel syndrome (IBS) is gaining attention, with recent studies indicating that certain probiotics or combinations may have mental health benefits for patients with IBS.
Aims: To systematically review and meta-analyze, using network meta-analysis (NWM), the comparative effectiveness and safety of probiotics with psychotropic potential on quality of life, depression, and anxiety in patients with IBS.
Methods: Relevant randomized controlled trials (RCTs) were analyzed, using a Bayesian NWM, to compare the performance of probiotics with mental health benefits in IBS treatment.
Cureus
August 2025
Biochemistry, Liaquat University of Medical and Health Sciences, Karachi, PAK.
Background: Vitamin D insufficiency is increasingly recognized as a significant and underlying contributor to a wide range of musculoskeletal disorders, particularly in gastrointestinal (GI) and endocrine health. The study aims to determine the clinical relationship between vitamin D status and the severity of GI symptoms, while also assessing the impact of related endocrine disturbances.
Methods: A cross-sectional study was conducted involving 120 adult patients with GI problems, including constipation, bloating, irritable bowel syndrome (IBS), and dyspepsia in a tertiary care hospital over a six-month duration.
Cureus
August 2025
Internal Medicine, Mayo Hospital, Lahore, PAK.
Background: Many published studies have shown that the prevalence of celiac disease (CD) is higher in individuals with irritable bowel syndrome (IBS); however, the current available evidence is controversial. Moreover, controversy exists regarding the routine screening of CD in IBS patients, as the available results show conflicting evidence. Objective: This study aimed to determine the prevalence of CD in individuals with IBS presenting at a tertiary care hospital.
View Article and Find Full Text PDF